Table 5.

Outcomes of Systemic DFO and IP DFO Treatment in Animal Models of PD at Various Doses and Dosing Intervals

source	animal model	formulation	dose administered	outcome
Dexter et al.75	male 6-OHDA Sprague—Dawley rats	0.9% saline delivered IP	30 mg/kg 2X/day I day prior to 6- OHDA lesion and for 4 days after	attenuated loss of striatal dopamine; attenuated the loss of dopaminergic neurons
Ward et al.14	male ferrocene-loaded Wistar rats	delivered IP	30 mg/kg 3X/week for 2 or 4 weeks after model induction	decrease in iron content in the SN, cerebellum, and cerebral cortex; reduced dopamine turnover and DOPAC
Xiong et al.76	male rotenone- induced PD Wistar rats	delivered IP	60 mg/kg/day for 8 weeks after model induction	inhibited iron accumulation in the SN, striatum globus pallidus, hippocampus, and cerebellum; reduced loss of TH- positive cells; protected dopaminergic neurons
Haleagrahara et al.77	male 6-OHDA Sprague—Dawley rats	delivered IP	50 mg/kg for 14 days beginning 48 h after surgery	significantly reversed decreases in striatal dopamine, glutathione (GSH), superoxide dismutase (SOD); significantly reversed the increase in protein carbonyl content (PCC); increased striatal neuronal number
Lv et al.78	male 6-OHDA Sprague—Dawley rats	delivered IP	50 mg/kg for 14 days beginning 48 h after surgery	attenuated loss of dopamine; decrease in PCC level; elevated GSH and SOD level; increased count of antioxidant enzymes